AASLD-话题@MedSci

#AASLD#

30篇内容 | 1648人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016522, encodeId=b2ae2016522fb, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD中国之声 | 聚焦多领域，多项成果在会上展示, objectType=article, longId=117233, objectId=835611e23349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=835611e23349, replyNumber=0, likeNumber=122, createdTime=2017-10-25, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=835611e23349, moduleTitle=AASLD中国之声 | 聚焦多领域，多项成果在会上展示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=835611e23349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016526, encodeId=d471201652622, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD2017: 又双叒叕刷存在感! “神药”阿司匹林可降低肝癌风险, objectType=article, longId=117412, objectId=8fab11e41269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fab11e41269, replyNumber=0, likeNumber=73, createdTime=2018-09-11, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fab11e41269, moduleTitle=AASLD2017: 又双叒叕刷存在感! “神药”阿司匹林可降低肝癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fab11e41269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016524, encodeId=da52201652438, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD2017 | HVPG可以预测NASH代偿期肝硬化患者的临床疾病进展, objectType=article, longId=117397, objectId=012411e39769, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012411e39769, replyNumber=0, likeNumber=69, createdTime=2017-12-15, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012411e39769, moduleTitle=AASLD2017 | HVPG可以预测NASH代偿期肝硬化患者的临床疾病进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012411e39769)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016519, encodeId=d93120165198b, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD2017 | 定量抗-HBc水平可预测慢乙肝停药后复发风险, objectType=article, longId=117193, objectId=e3fa11e1939d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3fa11e1939d, replyNumber=0, likeNumber=51, createdTime=2017-11-19, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3fa11e1939d, moduleTitle=AASLD2017 | 定量抗-HBc水平可预测慢乙肝停药后复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3fa11e1939d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016531, encodeId=99b92016531cd, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD2017 | 有TDF基线风险因素的慢乙肝初治患者应用TAF的疗效和安全性分析, objectType=article, longId=118039, objectId=ed9d11803991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed9d11803991, replyNumber=0, likeNumber=65, createdTime=2018-07-31, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed9d11803991, moduleTitle=AASLD2017 | 有TDF基线风险因素的慢乙肝初治患者应用TAF的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed9d11803991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016527, encodeId=347a201652eb4, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD2017 | 多重耐药慢乙肝：只要替诺福韦就够了？, objectType=article, longId=117521, objectId=6e2c11e52130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e2c11e52130, replyNumber=0, likeNumber=68, createdTime=2018-08-31, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e2c11e52130, moduleTitle=AASLD2017 | 多重耐药慢乙肝：只要替诺福韦就够了？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e2c11e52130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016518, encodeId=4748201651874, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=近期AASLD/NCCN/ACG/EASL/ESMO肝细胞癌指南解读, objectType=article, longId=72155, objectId=4910e2155ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4910e2155ba, replyNumber=0, likeNumber=0, createdTime=2017-01-26, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4910e2155ba, moduleTitle=近期AASLD/NCCN/ACG/EASL/ESMO肝细胞癌指南解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4910e2155ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016517, encodeId=3cfd201651e7a, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD 2015：丙肝新药Daklinza治疗晚期肝纤维化3型丙肝治愈率达100%, objectType=article, longId=59142, objectId=6c435914280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c435914280, replyNumber=0, likeNumber=62, createdTime=2016-09-26, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c435914280, moduleTitle=AASLD 2015：丙肝新药Daklinza治疗晚期肝纤维化3型丙肝治愈率达100%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c435914280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016516, encodeId=124b20165169f, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=Medscape：从2013 AASLD看肝病学十大亮点, objectType=article, longId=29033, objectId=d65b290333d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d65b290333d, replyNumber=0, likeNumber=68, createdTime=2014-09-10, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65b290333d, moduleTitle=Medscape：从2013 AASLD看肝病学十大亮点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65b290333d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016515, encodeId=430b20165159e, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=Hepatology：三联疗法或不再是丙肝标准方案 AASLD指南受挑战, objectType=article, longId=27376, objectId=329c2e376fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=329c2e376fa, replyNumber=0, likeNumber=70, createdTime=2013-12-18, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=329c2e376fa, moduleTitle=Hepatology：三联疗法或不再是丙肝标准方案 AASLD指南受挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=329c2e376fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016514, encodeId=82972016514b5, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=[AASLD 2012]血清HBsAg水平可指导干扰素治疗慢性乙肝, objectType=article, longId=12096, objectId=650a1209612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=650a1209612, replyNumber=0, likeNumber=75, createdTime=2013-04-05, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=650a1209612, moduleTitle=[AASLD 2012]血清HBsAg水平可指导干扰素治疗慢性乙肝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=650a1209612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016512, encodeId=2e6720165121a, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=2011年AASLD基因1型丙肝治疗指南更新（附全文）, objectType=article, longId=3223, objectId=906e322382, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=906e322382, replyNumber=0, likeNumber=88, createdTime=2012-02-02, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=906e322382, moduleTitle=2011年AASLD基因1型丙肝治疗指南更新（附全文）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=906e322382)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016511, encodeId=1ab82016511b3, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=新版AASLD血色病诊疗指南要点, objectType=article, longId=2975, objectId=fd4529e5e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd4529e5e2, replyNumber=0, likeNumber=85, createdTime=2011-12-13, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd4529e5e2, moduleTitle=新版AASLD血色病诊疗指南要点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd4529e5e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016513, encodeId=7e982016513ed, content=<a href='/topic/show?id=4bfc169010' target=_blank style='color:#2F92EE;'>#AASLD#</a>, objectTitle=AASLD 2011 急性肝衰竭指南更新及要点总结（附全文）, objectType=article, longId=3404, objectId=fbcc34045c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbcc34045c, replyNumber=0, likeNumber=71, createdTime=2012-05-02, rootId=0, userName=海豹, userId=3289320, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbcc34045c, moduleTitle=AASLD 2011 急性肝衰竭指南更新及要点总结（附全文）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbcc34045c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AASLD

2020-05-29

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD中国之声 | 聚焦多领域，多项成果在会上展示

2017-10-25

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD2017: 又双叒叕刷存在感! “神药”阿司匹林可降低肝癌风险

2018-09-11

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD2017 | HVPG可以预测NASH代偿期肝硬化患者的临床疾病进展

2017-12-15

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD2017 | 定量抗-HBc水平可预测慢乙肝停药后复发风险

2017-11-19

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD2017 | 有TDF基线风险因素的慢乙肝初治患者应用TAF的疗效和安全性分析

2018-07-31

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD2017 | 多重耐药慢乙肝：只要替诺福韦就够了？

2018-08-31

海豹 (审核中...)

前往app查看评论内容

#AASLD#

近期AASLD/NCCN/ACG/EASL/ESMO肝细胞癌指南解读

2017-01-26

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD 2015：丙肝新药Daklinza治疗晚期肝纤维化3型丙肝治愈率达100%

2016-09-26

海豹 (审核中...)

前往app查看评论内容

#AASLD#

Medscape：从2013 AASLD看肝病学十大亮点

2014-09-10

海豹 (审核中...)

前往app查看评论内容

#AASLD#

Hepatology：三联疗法或不再是丙肝标准方案 AASLD指南受挑战

2013-12-18

海豹 (审核中...)

前往app查看评论内容

#AASLD#

[AASLD 2012]血清HBsAg水平可指导干扰素治疗慢性乙肝

2013-04-05

海豹 (审核中...)

前往app查看评论内容

#AASLD#

2011年AASLD基因1型丙肝治疗指南更新（附全文）

2012-02-02

海豹 (审核中...)

前往app查看评论内容

#AASLD#

新版AASLD血色病诊疗指南要点

2011-12-13

海豹 (审核中...)

前往app查看评论内容

#AASLD#

AASLD 2011 急性肝衰竭指南更新及要点总结（附全文）

2012-05-02

科室
- - 订阅+
  - 更多科室
工具
服务